INR-101

N/A

Report date: 2025/09/08 16:21:24

NME

Base Information

Drug NameINR-101

Drug Alias NameINR101INR-101INR101 PET CTINR101-PET/CT

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsDiagnostic agentsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesYunhe Pharmaceutical (Tianjin) Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesYunhe Pharmaceutical (Tianjin) Co Ltd

Inactive CompaniesN/A

Active IndicationsDiagnostic agentsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A